Financial Performance - The company's operating revenue for the first half of 2022 was ¥614,740,089.46, representing a 4.67% increase compared to ¥587,330,610.63 in the same period last year[33]. - The net profit attributable to shareholders was ¥71,953,889.11, up 17.47% from ¥61,252,788.63 year-on-year[33]. - The net cash flow from operating activities surged by 217.75%, reaching ¥127,419,970.23 compared to ¥40,101,105.63 in the previous year[33]. - The basic earnings per share increased by 14.71% to ¥0.39 from ¥0.34 in the same period last year[33]. - Total assets at the end of the reporting period were ¥5,354,608,124.42, a 3.15% increase from ¥5,190,932,494.57 at the end of the previous year[33]. - Total profit reached 89 million yuan, reflecting an 18.50% growth year-over-year, while net profit was 72 million yuan, up 17.47%[53]. - The total assets increased by 3.15% to 5.355 billion yuan, and net assets grew by 0.45% to 4.431 billion yuan[53]. - The company achieved a consolidated revenue of 615 million yuan in the first half of 2022, an increase of 4.67% compared to the previous year[53]. - The company reported a total non-recurring profit and loss of 385,033.45 yuan after accounting for government subsidies and other income[38]. Research and Development - There is a significant investment in R&D for new products, particularly in the cardiovascular and chronic disease sectors, to counteract the anticipated decline in generic drug prices[13]. - Research and development investment rose by 7.71% to 64.5 million yuan, supporting the company's innovation efforts[72]. - The company aims to enhance its innovation capabilities, with expectations to obtain one more consistency evaluation approval and to submit additional applications for generic drugs[64]. - The company is focusing on R&D innovation to drive transformation, despite the long and uncertain nature of drug development cycles[104]. - The company is focusing on enhancing its research and development capabilities to innovate and introduce new technologies[200]. Market Strategy and Compliance - The company plans to enhance compliance management and adjust operational strategies in response to ongoing national healthcare reforms and procurement policies[8]. - The company is focusing on accelerating the consistency evaluation of its generic drugs to maintain market competitiveness amid expanding centralized procurement[10]. - The company emphasizes a dual-driven approach of production operations and capital operations to increase development momentum[47]. - The company is focusing on innovation and compliance management to adapt to the evolving pharmaceutical regulatory environment[42]. - The company has established a comprehensive risk control system to ensure safety, quality, and compliance in operations[66]. Environmental Compliance - Tianjin Lisheng Pharmaceutical Co., Ltd. reported a total wastewater discharge of 1.756 tons for chemical oxygen demand, exceeding the limit of 44.55 tons[116]. - The company recorded a total nitrogen discharge of 0.412 tons, with a limit of 7.303 tons, indicating compliance with environmental standards[116]. - The ammonia nitrogen discharge was 0.017 tons, well below the limit of 2.903 tons, demonstrating effective pollution control measures[116]. - The company has implemented measures to ensure that all emissions are within the prescribed limits, demonstrating commitment to environmental sustainability[116]. - The company has obtained environmental permits for multiple projects, including the expansion project and the addition of raw material drug varieties[118]. Investment and Asset Management - The company plans to accelerate the transfer of low-efficiency assets and is actively seeking potential buyers for its biopharmaceutical vaccine project[62]. - The company has a remaining unused fundraising amount of CNY 80,739,280, which is stored in a dedicated fundraising account[89]. - The company has invested CNY 39,007,000 in the Tianjin New Crown Pharmaceutical Co., Ltd. project, achieving a progress rate of 97.15%[92]. - The company has completed the acquisition of a 48% equity stake in a biochemical pharmaceutical company for CNY 3,536,000, achieving 100% of the investment commitment[92]. - The company plans to use 100.70 million yuan to replace self-raised funds previously invested in projects[95]. Risks and Challenges - The company faces risks from industry policy changes, including national medical system reforms and procurement policies, which may impact drug development and sales[102]. - There is a risk related to the completion of consistency evaluations for generic drugs, which could affect market competitiveness if not addressed[103]. - Rising production costs due to stricter standards and raw material price increases pose a significant risk to the company's operations[105]. - The implementation of national procurement policies is expected to lead to a decline in drug prices, increasing sales pressure on the company[106]. Corporate Governance and Shareholder Information - The company has not made any significant changes to the use of raised funds during the reporting period[90]. - The company reported a total guarantee amount of 4,000 million CNY during the reporting period, with the actual guarantee balance also at 4,000 million CNY[144]. - The company has no significant related party transactions during the reporting period, including asset or equity acquisitions and joint external investments[134][135]. - The company reported a total of 182,454,992 shares outstanding, with 100% being unrestricted shares[154]. - The total number of ordinary shareholders at the end of the reporting period was 18,781[156].

天津力生制药股份有限公司 2022 年第一季度报告全文 证券代码：002393 证券简称：力生制药 公告编号：2022-025 天津力生制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减 | | 营业收入（元） | 306,461,015.93 | 327,607,280.27 | -6.45% | | 归属于上市公司股东的净利润 | 41,953,999.32 | ...

Financial Performance - The company's operating revenue for 2021 was CNY 1,091,940,631.06, a decrease of 4.29% compared to CNY 1,140,837,555.39 in 2020[24] - Net profit attributable to shareholders increased significantly to CNY 122,105,336.50, representing a growth of 1,317.31% from CNY 8,615,268.42 in the previous year[24] - The total profit reached CNY 137 million, an increase of 343.30% year-over-year[44] - Net profit for the year was CNY 122 million, reflecting a significant growth of 1317.31% compared to the previous year[44] - Basic earnings per share increased to CNY 0.67, a 1,240% increase compared to CNY 0.05 in the previous year[25] - The company reported a weighted average return on equity of 2.80%, up from 0.20% in the previous year[25] - The total assets reached CNY 5,190,932,494.57, representing a 3.36% increase from CNY 5,022,182,988.99 at the end of the previous year[25] - The net assets rose to CNY 4.411 billion, marking a growth of 2.52% from the previous year[44] Cash Flow and Investments - The net cash flow from operating activities reached CNY 196,336,646.56, up by 157.09% compared to CNY 76,370,096.49 in 2020[24] - The net cash flow from operating activities in the fourth quarter was CNY 81,866,782.19, showing strong cash generation capabilities[29] - Investment activity cash inflow surged by 866.34% to ¥82,120,673.81 in 2021 from ¥8,498,107.19 in 2020[73] - The total investment amount for the reporting period was 68,780,609.30 CNY, representing a 23.91% increase compared to the previous year's investment of 55,506,724.74 CNY[82] Research and Development - The company aims to invest more in R&D for new products, particularly in the cardiovascular and chronic disease sectors, to counteract the pressure from declining drug prices[11] - The company invested CNY 104 million in R&D, focusing on overcoming technical challenges and enhancing self-research capabilities[49] - The R&D strategy includes building a high-quality talent team and combining independent and collaborative research to mitigate risks associated with new product development[9] - The company is focusing on developing high-tech controlled-release generic drugs to enhance its market competitiveness[71] Market Strategy and Product Development - The company plans to enhance compliance management and adjust operational strategies in response to ongoing national healthcare reforms and procurement policies[7] - There is a focus on accelerating the consistency evaluation of generic drugs to maintain market competitiveness amid expanding centralized procurement[8] - The company will continue to optimize its product structure and enhance marketing strategies to improve sales quality and market competitiveness[11] - The company is focused on expanding its product offerings and enhancing its market presence in the pharmaceutical sector[38] Corporate Governance and Compliance - The company emphasizes innovation and quality as key components for high-quality development in the pharmaceutical industry[36] - The company maintains a governance structure that complies with relevant laws and regulations, ensuring independent operation from its controlling shareholder[116] - The company has established a transparent performance evaluation and incentive mechanism for its directors and management, promoting accountability[120] - The company ensures timely and accurate information disclosure, allowing all shareholders equal access to information[122] Social Responsibility and Environmental Compliance - The company has been actively involved in social responsibility initiatives, including disaster relief and community support programs[179] - The company has implemented a self-monitoring plan for environmental compliance, including both manual and automatic monitoring methods[178] - The total amount of wastewater discharged was 5.2475 tons for chemical oxygen demand, 0.1649 tons for ammonia nitrogen, and 1.6661 tons for total nitrogen, all within the pollution discharge standards[177] Employee and Management Structure - The total number of employees at the end of the reporting period was 1,477, with 830 in the parent company and 647 in major subsidiaries[155] - The company has implemented a comprehensive training program focusing on GMP, GVP, and safety regulations to enhance employee skills[157][158] - The company has a strong management team with extensive experience in the pharmaceutical industry, including roles in research, sales, and general management[133] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[137] - New product launches are expected to contribute an additional 300 million RMB in revenue over the next year[137] - The company is considering strategic acquisitions to enhance its product portfolio and market presence[137]

天津力生制药股份有限公司 2021 年第三季度报告 证券代码：002393 证券简称：力生制药 公告编号：2021-038 天津力生制药股份有限公司 2021 年第三季度报告 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公告不存在 虚假记载、误导性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年 同期增减 | 年初至报告期末 | 年初至报告期末 比上年同期增减 | | --- | --- | --- | --- | --- | | 营业收入（元） | 248,328,474.55 | -17.66% | 835,659,085.18 | -8.71% | | ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 587.33 million, a decrease of 4.32% compared to CNY 613.86 million in the same period last year[26]. - The net profit attributable to shareholders increased by 8.28% to CNY 61.25 million, up from CNY 56.57 million year-on-year[26]. - The net cash flow from operating activities decreased significantly by 44.86% to CNY 40.10 million, compared to CNY 72.73 million in the previous year[26]. - The total assets at the end of the reporting period were CNY 5.09 billion, reflecting a 1.38% increase from CNY 5.02 billion at the end of the previous year[26]. - The net assets attributable to shareholders increased by 0.98% to CNY 4.34 billion, compared to CNY 4.30 billion at the end of the previous year[26]. - The company achieved a 100% pass rate in product quality inspections during the first half of the year, maintaining high standards[46]. - The total profit for the first half of 2021 was CNY 75.17 million, compared to CNY 68.02 million in the same period of 2020, marking an increase of 10.5%[140]. - The company reported a comprehensive income total of CNY 86.62 million for the first half of 2021, up from CNY 71.16 million in the same period of 2020, reflecting a growth of 21.7%[144]. Research and Development - The company invested approximately 60 million yuan in research and development in the first half of 2021, focusing on the treatment of chronic diseases[43]. - Research and development expenses rose significantly by 49.98% to ¥59,886,219.54, reflecting increased investment in R&D projects[51]. - The company plans to continue investing in new product development and market expansion strategies to drive future growth[139]. - The R&D expenditure for the first half of 2021 was approximately 200 million yuan, accounting for 7.1% of total revenue, aimed at enhancing product pipeline[156]. Market Strategy and Compliance - The company plans to enhance compliance management and adjust operational strategies in response to ongoing national healthcare reforms and procurement policies[7]. - The company is focusing on accelerating the consistency evaluation of its generic drugs to maintain market competitiveness amid expanding centralized procurement[8]. - The company is adapting to the evolving pharmaceutical industry landscape, focusing on compliance and quality to navigate increased competition and regulatory changes[38]. - The company is actively expanding its market presence by strengthening strategic partnerships with leading pharmaceutical distributors and enhancing its marketing capabilities[41]. Financial Management and Investments - The company does not plan to distribute cash dividends or issue bonus shares for the reporting period[13]. - The cash and cash equivalents decreased significantly by 420.92% to -¥78,528,654.83, indicating challenges in cash flow management[52]. - The company invested ¥42,591,546.75 during the reporting period, a significant increase of 115.00% compared to ¥18,817,655.88 in the same period last year[62]. - The ongoing construction project for the Cangzhou raw material drug base has seen an investment of ¥42,591,546.75, with a total actual investment of ¥127,936,383.61 to date[63]. Risks and Challenges - The company faces risks from ongoing national healthcare reforms, including volume-based procurement and consistency evaluations, which significantly impact drug R&D, production, and sales[70]. - Rising production costs due to stricter drug production and environmental standards pose a risk, prompting the company to implement lean production practices to enhance efficiency and reduce costs[72]. - The company anticipates continued price declines for generic drugs due to national procurement policies, leading to increased investment in new product development, particularly in the cardiovascular and chronic disease sectors[72]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,259[119]. - Tianjin Jinhao Pharmaceutical Co., Ltd. holds 51.36% of the shares, amounting to 93,710,608 shares[119]. - The company has not engaged in any securities or derivative investments during the reporting period[65][66]. - The company has not sold any significant assets or equity during the reporting period[67]. Asset and Liability Management - The total assets of the company reached 900,540,000 CNY, showing a robust asset base for future growth[162]. - The total liabilities stood at CNY 747,461,132.54, up from CNY 720,087,231.30, reflecting an increase of approximately 3.41%[132]. - The company's non-current assets totaled CNY 2,794,052,307.30, slightly up from CNY 2,777,812,908.95, indicating a growth of about 0.58%[131]. Corporate Governance and Compliance - The company has a history of compliance with regulatory requirements, as evidenced by its successful public listing and capital verification[167]. - The company has not implemented any stock incentive plans or employee stock ownership plans during the reporting period[79]. - There were no significant litigation or arbitration matters during the reporting period[92].

天津力生制药股份有限公司 2021 年第一季度报告全文 天津力生制药股份有限公司 2021 年第一季度报告 2021 年 04 月 1 天津力生制药股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人徐道情、主管会计工作负责人王家颖及会计机构负责人(会计主 管人员)王家颖声明：保证季度报告中财务报表的真实、准确、完整。 2 天津力生制药股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 327,607,280.27 | 332,679,628.71 | -1.52% | | 归属于上市公司股东的净利润（元） | 36,054,500.57 | 34,252,525.69 | 5.26% ...

Financial Performance - The company reported a total revenue of CNY 1.14 billion in 2020, a decrease of 29.37% compared to CNY 1.62 billion in 2019[22]. - Net profit attributable to shareholders was CNY 8.62 million, down 95.42% from CNY 188.14 million in the previous year[22]. - The net cash flow from operating activities was CNY 76.37 million, a decline of 71.54% from CNY 268.33 million in 2019[22]. - The company’s total assets at the end of 2020 were CNY 5.02 billion, a decrease of 4.75% from CNY 5.27 billion at the end of 2019[22]. - The net assets attributable to shareholders were CNY 4.30 billion, down 2.60% from CNY 4.42 billion at the end of 2019[22]. - In Q4 2020, the company experienced a net loss of CNY 70.55 million, contrasting with profits in the first three quarters[26]. - The company reported a total operating revenue for 2020 of ¥1,140,837,555.39, a decrease of 29.37% compared to ¥1,615,276,373.24 in 2019[52]. - The revenue from tablets was ¥834,696,353.00, accounting for 73.17% of total revenue, with a year-on-year decline of 35.79%[53]. - The company achieved a gross margin of 61.48% in the pharmaceutical manufacturing sector, down by 10.80% from the previous year[55]. - The sales revenue in the North China region was ¥491,063,718.07, representing 43.04% of total revenue, with a decrease of 35.31% year-on-year[53]. Dividend Policy - The company reported a cash dividend of 1 RMB per 10 shares for a total of 182,454,992 shares as of December 31, 2020[12]. - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares, totaling 18,245,499.20 yuan, which represents 211.78% of the net profit attributable to ordinary shareholders[115]. - The cash dividend policy has been executed in accordance with the company's articles of association, ensuring transparency and protection of minority shareholders' rights[114]. - The company has maintained a consistent cash dividend distribution over the past three years, with the 2020 distribution being the lowest compared to previous years[117]. Market Challenges and Strategies - The company faces risks from national medical system reforms, including volume-based procurement and price control policies, which may impact drug development and sales[7]. - The company anticipates continued pressure on drug prices due to national procurement policies, prompting increased investment in new product development in the cardiovascular and chronic disease sectors[11]. - The company emphasizes the importance of completing consistency evaluations for generic drugs to maintain market competitiveness, given the ongoing national drug procurement expansion[8]. - The company will strengthen compliance management and adjust operational strategies to adapt to industry policy changes and improve operational quality and efficiency[7]. - The company aims to optimize its product structure and accelerate the launch of new products to seize market opportunities and enhance sales quality[11]. Research and Development - The company is committed to innovation and aims to enhance its R&D capabilities to mitigate risks associated with long development cycles and high investment in new drug development[9]. - The company has a strong focus on building a high-quality R&D team and fostering collaboration to advance new product development and approval processes[9]. - The company plans to enhance innovation capabilities by increasing R&D investment and completing 4 active pharmaceutical ingredient projects within the year, improving supply chain control[104]. - The company is investing in R&D, with a budget allocation of RMB 100 million for the development of new drugs and technologies in the upcoming year[200]. Operational Efficiency - The company plans to implement lean production practices to improve efficiency and reduce production costs amid rising raw material prices and stricter production standards[10]. - The production efficiency of the packaging line improved by 24% through lean production initiatives[49]. - The company aims to improve production efficiency through lean management and effective cost control, with a focus on safety and quality management[105]. - Operational efficiency initiatives have led to a reduction in production costs by 10%, enhancing overall profitability[147]. Corporate Governance and Compliance - The company has established a risk management mechanism to improve operational quality and ensure compliance with annual budget goals[107]. - The company is committed to maintaining high standards in corporate governance with the recent appointments of independent directors[197]. - The company has made commitments to avoid any competition with Tianjin Lisheng Pharmaceutical, ensuring that its subsidiaries do not engage in competing activities[120]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[122]. Community and Environmental Responsibility - The company provided financial support of 140,000 yuan to impoverished villages in Ninghe District as part of its poverty alleviation efforts[159]. - During the pandemic, the company and its affiliated enterprises donated over 52,500 yuan through 367 contributions[158]. - The company has a hazardous waste disposal capacity of 241.35 tons, with all waste managed according to national standards[163]. - The company is actively involved in community support and social responsibility initiatives, including disaster relief efforts[158]. Future Outlook and Growth Initiatives - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[200]. - Future outlook indicates a projected revenue growth of 10% for 2021, driven by new product launches and market expansion strategies[200]. - The company aims to introduce three new products in the next quarter, which are anticipated to contribute an additional 200 million RMB in revenue[147]. - The company is optimistic about future growth prospects, supported by its strategic initiatives and management expertise[196].

天津力生制药股份有限公司 2020 年第三季度报告全文 2020 年第三季度报告 2020 年 10 月 1 天津力生制药股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告 内容的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗 漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人徐道情、主管会计工作负责人王家颖及会计机构负责 人(会计主管人员)王家颖声明：保证季度报告中财务报表的真实、准 确、完整。 2 天津力生制药股份有限公司 2020 年第三季度报告全文 天津力生制药股份有限公司 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上 年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,198,240,651.10 | 5,272,702,523.46 | | -1.41% | | 归属于上市公司股东的净资产（元） | 4,440, ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 613,859,637.68, a decrease of 28.21% compared to CNY 855,026,310.95 in the same period last year[27]. - The net profit attributable to shareholders of the listed company was CNY 56,567,032.86, down 36.34% from CNY 88,856,429.54 year-on-year[27]. - The net cash flow from operating activities was CNY 72,730,531.90, a decline of 37.87% compared to CNY 117,061,094.58 in the previous year[27]. - The basic earnings per share decreased to CNY 0.31, down 36.73% from CNY 0.49 in the same period last year[27]. - The total profit was 68.02 million yuan, down 35.97% year-on-year, while net profit was 56.57 million yuan, a decline of 36.34%[45]. - The gross profit margin for the pharmaceutical segment was 63.95%, down 7.33% year-on-year, with a revenue decrease of 28.21% and a cost reduction of 9.88%[55]. - The company reported a net increase in cash and cash equivalents of ¥24,470,144.15, a decline of 25.22% compared to ¥32,721,329.76 in the previous year[54]. - The company reported a total investment of 69,996,000 RMB in the new coronavirus pharmaceutical raw materials and formulations project, with an actual investment of 63,661,740 RMB, achieving a progress rate of 90.95%[77]. Investment and Development - The company plans to increase investment in new product development, particularly in the cardiovascular and chronic disease sectors, to enhance market competitiveness[13]. - The company has committed to invest CNY 86,768,400 in various projects, with CNY 57,640,000 already invested[73]. - The company is currently constructing a new drug base, with a total investment of CNY 7,518,150 planned[66]. - The company has established a complete industrial chain by self-producing the raw materials needed for its main products, ensuring quality and reducing production costs[41]. - The company plans to enhance market expansion by adjusting marketing strategies and increasing coverage in grassroots medical and retail terminals[48]. Compliance and Risk Management - The company will strengthen compliance management and adjust operational strategies in response to ongoing healthcare reforms and procurement policies[8]. - The company is facing risks from industry policy changes, including national medical system reforms and centralized procurement, which may significantly impact drug R&D, production, and sales[83]. - The company emphasizes the importance of completing the consistency evaluation of generic drugs to maintain market competitiveness, as failure to do so could lead to a loss of market share[84]. - The company has committed to ensuring that any transactions with related parties will adhere to fair market principles and will be conducted at reasonable prices[96]. Environmental and Social Responsibility - The company provided financial support of 70,000 RMB to poverty-stricken villages in Ninghe District, Banjiao Town[130]. - The company has established a closed and hardened hazardous waste storage facility, compliant with national standards[127]. - The company has implemented an emergency response plan for environmental incidents, approved by the local environmental bureau[127]. - The total hazardous waste generated in the first half of 2020 was 74.8 tons, with proper disposal measures in place[127]. Shareholder and Equity Information - The company did not distribute cash dividends or issue bonus shares for the reporting period[15]. - The company has a total of 182,454,992 shares, with 100% being unrestricted shares[141]. - The company has 19,209 ordinary shareholders as of the report date[143]. - The company has not reported any major changes in its subsidiaries during the reporting period[138]. - The company has not implemented any share repurchase or reduction during the reporting period[142]. Operational Efficiency - The company aims to improve production efficiency and reduce costs through lean production practices amid rising production costs[12]. - The company aims to improve cost control and efficiency through the application of OEE and TPM, focusing on improving yield and labor utilization rates[48]. - The company will conduct regular safety inspections to ensure stable safety production conditions and enhance quality management systems[48]. Research and Development - R&D investment decreased by 42.57% to ¥39,929,137.89 from ¥69,523,829.25 in the previous year, attributed to higher R&D spending in the same period last year[54]. - The company is committed to innovation and R&D to facilitate its transformation, despite the long and uncertain nature of drug development cycles[86]. - The implementation of centralized procurement policies is expected to lead to a decline in generic drug prices, which will pressure the company's sales; the company plans to increase R&D investment in new products targeting chronic diseases[88].

证券代码：002393 证券简称：力生制药 公告编号：2020-044 天津力生制药股份有限公司 关于举行"投资者网上集体接待日"活动公告 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公告不 存在虚假记载、误导性陈述或者重大遗漏。 天津力生制药股份有限公司（以下简称"公司"）为便于广大投资者更深入全面地了解 公司情况，公司定于 2020 年 6 月 10 日（周三）15:00-16:30 举行"投资者网上集体接待日" 活动，现将有关事项公告如下： 本次"投资者网上集体接待日"活动将在深圳市全景网络有限公司提供的网上平台采取 网络远程的方式举行，投资者可登录"全景• 路演天下"（http://rs.p5w.net）参与本次互动 交流。 出席本次"投资者网上集体接待日"活动的人员有：董事、总经理王福军先生，独立董 事田昆如先生，董事会秘书马霏霏女士和副总会计师丁雪艳女士。 欢迎广大投资者积极参与。 特此公告。 天津力生制药股份有限公司 2020 年 6 月 5 日 ...